Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Cash & Equivalents (2016 - 2025)

UroGen Pharma (URGN) has disclosed Cash & Equivalents for 10 consecutive years, with $110.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 35.61% year-over-year to $110.7 million, compared with a TTM value of $110.7 million through Dec 2025, down 35.61%, and an annual FY2025 reading of $110.7 million, down 35.61% over the prior year.
  • Cash & Equivalents was $110.7 million for Q4 2025 at UroGen Pharma, up from $90.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $220.0 million in Q2 2024 and bottomed at $20.1 million in Q2 2023.
  • Average Cash & Equivalents over 5 years is $87.8 million, with a median of $91.5 million recorded in 2025.
  • The sharpest move saw Cash & Equivalents plummeted 65.33% in 2023, then skyrocketed 992.92% in 2024.
  • Year by year, Cash & Equivalents stood at $44.4 million in 2021, then grew by 24.91% to $55.4 million in 2022, then soared by 71.46% to $95.0 million in 2023, then soared by 81.04% to $172.0 million in 2024, then crashed by 35.61% to $110.7 million in 2025.
  • Business Quant data shows Cash & Equivalents for URGN at $110.7 million in Q4 2025, $90.0 million in Q3 2025, and $92.9 million in Q2 2025.